Published online Apr 27, 2009.
https://doi.org/10.4068/cmj.2009.45.1.47
The Role of PTEN Mutation in the Development of Endometrial Carcinoma
Abstract
Over the past 2 decades, the tendency has been to classify endometrial carcinoma into 2 different types. Type I tumors (about 80%) are endometrioid carcinomas, are often preceded by complex and atypical hyperplasia, and are associated with estrogen stimulation. Type II tumors (about 10%) are nonendometrioid carcinomas that arise occasionally from precancerous lesions that develop in atrophic endometria. It has been found that the molecular alterations of endometrioid carcinomas, including defects in DNA-mismatch repair and mutations in PTEN (phosphatase and tension homologue deleted in chromosome ten), K-ras, and beta-catenin, are different from those of the nonendometrioid carcinomas. In this study, we analyzed the PTEN mutation by direct DNA sequencing of the endometrial hyperplasia and endometrioid carcinoma in order to investigate the molecular carcinogenesis of Type I endometrial carcinoma. PTEN mutations were detected in 14 (37.8%) of 37 carcinomas, including 8 cases (21.6%) in exon 5, 1 case (2.7%) in exon 6, 5 cases (13.5%) in exon 7, and 3 cases (8.1%) in exon 8. The most frequent site of PTEN mutation was codon 130 on exon 5, which encodes the tyrosine phosphatase catalytic domain. The PTEN mutation was not associated with histologic grade, depth of invasion, or clinical stage. PTEN mutations were also shown in 3 cases (15.8%) of 19 typical endometrial hyperplasias and in 6 cases (28.6%) of 21 atypical endometrial hyperplasias. These results suggest that PTEN is an important target gene in the development of type I endometrial carcinomas and that the presence of PTEN mutations in typical and atypical endometrial hyperplasia suggest that PTEN mutations would occur as early events in the process of type I endometrial carcinogenesis.
Fig. 1
On electrophoresis, each PCR product of PTEN gene was located in 375 bp for exon 5 (lane 1), 275 bp for exon 6 (lane 2), 241 bp for exon 7 (lane 3) and 399 bp for exon 8 (lane 4) of PTEN gene (M; 100 bp ladder marker).
Fig. 2
Examples of conversion, hetero-form, and insertion. A G-to-A conversion in exon 5 of PTEN gene resulted in a nonsense mutation in endometrial carcinoma. An A-to-G transition in exon 5 caused a missense mutation. An insertion of A in exon 7 generally occurred in non-coding region.
Table 1
Primers of PTEN
Table 2
Mutation of PTEN in endometrial carcinoma
Table 3
Mutation of PTEN of endometrial carcinoma according to pathologic parameters
Table 4
Mutation of PTEN in endometrial hyperplasia
References
-
Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10–17.
-
-
Okamoto A, Sameshima Y, Yamada Y, Techima S-I, Terashima Y, Terada M, et al. Allelic loss of chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632–5635.
-
-
Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Path 1997;150:177–185.
-
-
Fujino T, Risinger JI, Collins NK, Liu F-S, Nishii H, Takahashi H, et al. Allelotype of endometrial carcinoma. Cancer Res 1994;54:4294–4298.
-
-
Peiffer SL, Heraog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goddfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 1995;55:1922–1926.
-
-
Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the uterus. Cancer Res 1991;51:5308–5314.
-
-
Enomoto T, Fujita M, Inoue M, Rice JM, Nakajima R, Tanizawa O, et al. Alterations of the p53 tumor suppressor gene and its association of the c-K-ras protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993;53:1883–1888.
-
-
Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK. Early mutational activation of the c-ki-ras oncogene in endometrial carcinoma. Cancer Res 1994;54:1604–1607.
-
-
Catastis LI, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas. Clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160–1164.
-
-
Machin P, Catasús LI, Pons C, del Rio E, Matias-Guiu X, Prat J. Beta-catenin mutations and expression in endometrial carcinomas with and without microsatellite instability. 90th Annual meeting; Atlanta. USCAP; 2001.(Abstract).
-
-
Weng LP, Smith WM, Dahia PL, Jiebold U, Gil E, Lees JA, et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 1999;59:5808–5814.
-
-
Tamura M, Gu J, Takahasi T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of Focal Adhesion Kinase and p130cas. Cancer Res 1999;59:442–449.
-
-
Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, Baker SJ. PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 2001;61:4569–4575.
-
-
Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;15:5932–5935.
-
-
Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001;7:2636–2642.
-
-
Tashiro H, Blazes MS, Wu Rong, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935–3940.
-
-
Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254–3258.
-
-
Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 1998;58:2500–2503.
-